Probiotics for Prevention of Ventilator-Associated Pneumonia (VAP)

Mahidol University150 enrolled

Overview

Hospitalized patients with ventilator are randomized to receive fermented dairy product containing L. casei shirota or nothing. The main outcome is development of ventilator-associated pneumonia (VAP)

Fermented dairy product containing L. casei shirota has bee shown to inhibit multi-drug-resistant bacteria. This study is conducted to determine if Fermented dairy product containing L. casei shirota can prevent ventilator-associated pneumonia.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

150

Conditions

Drug Safety

Interventions

ProbioticsOTHER

80 ml of fermented dairy product containing L. casei shirota via nasogastric tube once daily and 80 ml of fermented dairy product containing L. casei shirota oral rinse once daily

controlOTHER

usual oral care

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patient age ≥ 18-year who received ventilator and agreed to participate by signing informed consent form Exclusion Criteria: Immunocompromised host (e.g. HIV infection, On immunosupressive agents, ANC ≤ 500 cell/ml), Pregnancy, History of congenital heart disease, rheumatic fever, previously infective endocarditis, prosthetic valve, Contraindication for enteral feeding, History of milk or milk-product allergy

Locations (1)

Siriraj Hospital

Bangkok, Bangkok, Thailand

RECRUITING

Outcomes

Primary Outcomes

Number of subjects with pneumonia

patient with pneumonia

Time frame: up to 28 days

Central Contacts

Visanu Thamlikitkul, MD

CONTACT

662-412-5994 sivth@mahidol.ac.th

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.